PT-141
Bremelanotide
PT-141 (bremelanotide) is a first-of-its-kind sexual-health peptide — it works on <b>desire in the brain</b>, not blood flow, which makes it fundamentally different from Viagra-style drugs. It's even FDA-approved (as Vyleesi) for a specific indication. This guide covers how PT-141 works, what the research shows, dosing references, safety and status.
PT-141 quick facts
| Reported research dosing | 0.5mg-2mg |
| Route | Subq |
| Cycle length | - |
| Frequency | As Needed · As Needed |
| Half-life | ~2–3 hrs |
| Forms | Injectable, Nasal |
| Evidence level | FDA-approved (Vyleesi); human |
Central libido lever for men and women. Flushing/nausea track with dose — start low.
How PT-141 works
PT-141 is derived from alpha-melanocyte-stimulating hormone (α-MSH) and acts as a melanocortin-receptor agonist, primarily at MC4R in the hypothalamus and limbic system — the brain circuitry behind sexual desire and arousal. The crucial distinction: it works centrally on desire, not on vascular smooth muscle. That's what separates it mechanistically from PDE5 inhibitors like sildenafil (Viagra) and tadalafil, which act on blood flow. PT-141 targets the 'wanting,' not just the 'plumbing.'
What the research & approval show
PT-141 has real clinical validation: as Vyleesi, bremelanotide was FDA-approved in June 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first approved on-demand treatment for HSDD. Because its mechanism is desire-based and central, off-label interest has expanded to men with low libido or erectile dysfunction that doesn't fully respond to PDE5 inhibitors, and it's sometimes combined with them since the mechanisms are complementary.
PT-141 dosing (research reference)
As the approved Vyleesi, bremelanotide is given by subcutaneous auto-injector on demand, at least 45 minutes before anticipated activity, with a defined maximum frequency (not daily). Research-market PT-141 is also seen in nasal-spray form. It's reconstituted with bacteriostatic water where injectable; the calculator above converts a research amount into syringe units. This summarizes existing references for education only, not dosing advice.
Safety & side effects
The most common effects are nausea (fairly frequent, especially early), flushing and headache. Because it acts on melanocortin receptors, it can cause a transient rise in blood pressure (so it's cautioned in uncontrolled hypertension or cardiovascular disease) and, via MC1R, temporary skin/gum darkening with repeated use. These are worth understanding before use, and it's a prescription product for a reason.
Related compounds
PT-141 shares the melanocortin family with the tanning peptides Melanotan I/II (which hit MC1R for pigmentation). For sexual health specifically, PT-141 is unique in acting on desire centrally rather than on blood flow like the PDE5-inhibitor drugs.
Legal & regulatory status
Bremelanotide is FDA-approved as Vyleesi for HSDD in premenopausal women — a prescription medication. Use outside that indication (e.g., in men) is off-label, and PT-141 sold on the research-chemical market is unapproved research material. Follow the laws and medical guidance that apply to you.
✅ Clinically validated
- FDA-approved as Vyleesi (bremelanotide) for hypoactive sexual desire disorder in premenopausal women, on the RECONNECT phase-3 programme. The effect size was statistically significant and modest — a meaningful improvement for a minority rather than a transformation for most.
- Nausea was the dominant adverse event, affecting roughly 40% of participants and causing a substantial share of the discontinuations.
📊 Correlative data
- Used far beyond the licensed population — men, and women outside the approved indication — where there are no trials. Reported experience is consistent about two things: it works on desire rather than on mechanics, and the nausea is dose-related and real.
- Flushing and transient blood-pressure rise are frequently reported, matching the trial data.
🧪 Theoretical / extrapolated
- A melanocortin receptor agonist acting centrally — on MC3R and MC4R in the hypothalamus — not on vascular smooth muscle. That is the key mechanistic distinction from the PDE5 inhibitors: it addresses desire, they address blood flow, and they are not substitutes for each other.
- MC1R activity is why some users report darkening of moles and freckles, and the shared melanocortin mechanism is why stacking it with Melanotan is predicted to compound that.
These tiers tell you how much human evidence exists — not how well something works. This is the research space, and most of what’s in here is new rather than disproven. Something sitting at “theoretical” usually means nobody has funded the trial, not that the trial was run and failed.
The trap runs the other way too: something can be clinically validated and still do very little for you specifically. A statistically significant result in a study population is not a promise about your body.
- ✅ Clinically validated — human randomised trials or meta-analyses support it. The strongest footing available.
- 📊 Correlative — observational or epidemiological data. Suggestive, and genuinely useful for direction, but it cannot establish cause.
- 🧪 Theoretical / mechanistic — the mechanism is understood and often demonstrated in cells or animals, and the human trial doesn’t exist yet. Unproven is not the same as ineffective. Plenty of what’s standard practice today sat here five years ago.
✗ is a safety flag, not a grade. Where you see it, the concern is harm — not a disappointing trial. A compound tested for one purpose and found not to help there can still be worth studying somewhere else, so a negative result never gets rendered as a cross. It sits alongside the tier, because something can be both well-studied and genuinely risky.
My job is to tell you which one you’re looking at, and let you make the call. Grading something low isn’t me dismissing it — it’s me refusing to oversell it. This is the research space, and being able to reason forward from a mechanism matters as much as waiting for the trial.
PT-141 — safety, predicted from mechanism
Much of this compound class has never been through a human safety trial. Rather than say nothing — or print a generic warning — this is what its known mechanism predicts could go wrong, and what you can do about it. Predictions are labelled as predictions.
What the mechanism predicts
Derived from what this molecule does, not from a trial.
- These are melanocortin receptor agonists and they are not selective, which is the whole safety story. MC1R gives the tanning. MC4R gives the nausea, the flushing and the erections. You do not get to choose which receptors respond.
- The mole question is the one that matters. These drive melanogenesis systemically — existing naevi commonly darken and new ones can appear. That is not itself cancer, but it makes melanoma surveillance harder precisely in people using a tanning agent.
What has actually been reported
- Nausea in the first hours after dosing is very common and usually settles with repeated exposure. Facial flushing, spontaneous erections and appetite suppression are all frequently reported.
- Case reports exist of melanoma diagnosed in Melanotan users. Causation is not established and the population self-selects for sun exposure — but 'unproven' is not 'reassuring' here.
How to reduce the risk
Each of these follows from the same mechanism as the prediction.
- Get a full-body skin check before you start, and photograph your moles. This is the whole mitigation. The predicted problem is that melanogenesis makes surveillance harder — a dated set of baseline photographs is what makes 'has this changed?' answerable later.
- Start at a fraction of the intended dose. The nausea and flushing are MC4R effects that attenuate with exposure, so almost everyone who has a miserable first experience simply started too high.
- Dose in the evening. If the nausea lands, you sleep through the worst of it.
- Sun protection does not become optional because you tan faster. Melanin is partial protection, and the tan is not the part that matters here — the mole surveillance is.
- Any new lesion, or an existing one that changes shape, colour or border, is a dermatologist appointment rather than a forum question.
What it does to your bloodwork
A fact about the assay, not a guess about the drug.
- No routine marker tracks this. The monitoring here is dermatological, not haematological — get a skin check and photograph your moles before you start.
Don't run this if
- Personal or family history of melanoma, or many atypical moles.
- Any pigmented lesion you have not had looked at.
The honest unknown
- Whether driving melanogenesis for years changes melanoma risk in humans. Nobody has run that study and it is not obvious anyone will.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Food is not a factor — pick a time you will keep
Nothing you eat touches a subcutaneous injection, so there is no meal to plan around. What does matter is a fixed slot: the commonest reason an injectable protocol underperforms is missed doses, not mistimed ones.
With a short half-life, dose it near the effect you want rather than at a fixed hour.
Derived from half-life, route and mechanism — not from a dosing trial. Reasoned, and labelled as reasoned.
PT-141 reconstitution calculator
Research reconstitution calculator
Where to get PT-141
Buy PT-141 at AminoWell USA →PT-141 — interference & stacking
Predicted from mechanism, not from an interaction study. There are no trials of these combinations — what follows is what the biology implies, so treat it as a reason to watch something, not as a finding.
What PT-141 moves on your bloodwork
These are the markers this compound is expected to move, and which direction. Knowing that in advance is mostly about NOT panicking: some of these moving is the compound working.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Blood pressure is the thing to watch here and it is not a lab — melanocortin agonists can raise it transiently after dosing.
What to do: Take blood pressure before and an hour after a dose the first few times. That tells you more than any panel.
- Which compounds push the same lever, and why the dose adds up faster than people count
- What blunts it — the stacks that waste your money
- What compounds the risk, so a side effect arrives sooner than any one of them suggests
- Coach Cam's read on running it alongside the rest of your protocol
Get the complete breakdown for PT-141 — inside the Academy alongside the full interactive Vault.
Unlock in the Academy — $10/mo →The mechanism-predicted concern that matters is not on a blood panel: melanocortin agonists stimulate melanocytes, so existing moles darkening or changing is the signal to take seriously, and a skin check before starting is the version of a baseline that applies here.
Bloodwork to run alongside PT-141
Run these before you start, and again after 8–12 weeks. A baseline you didn’t take is one you can never go back for.
| Marker | What it’s watching for |
|---|---|
| Total Testosterone | Rule out the hormonal cause before treating the symptom |
| Free Testosterone | The fraction that actually acts |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Erectile difficulty is a vascular warning — this is the vascular check |
| HbA1c (Hemoglobin A1c) | Diabetes is a leading cause, and it's silent for years |
The ED & Low Libido panel covers these in one order — 11 markers, $202.45 with the discount applied.
Check results you already have → · All 102 markers A–Z
PT-141 — frequently asked questions
What is PT-141 (bremelanotide)?
PT-141 is a melanocortin-receptor agonist peptide for sexual health that acts on desire in the brain. It's FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.
How does PT-141 work?
It activates MC4R in the hypothalamus/limbic system — the brain circuitry of sexual desire and arousal. Unlike Viagra-type drugs, it works centrally on desire, not on blood flow, so it targets 'wanting,' not just erectile plumbing.
Does PT-141 work for men?
Its FDA approval (Vyleesi) is for premenopausal women with HSDD. Off-label, it's used by men for low libido or ED that doesn't fully respond to PDE5 inhibitors, and sometimes combined with them since the mechanisms are complementary. That use is off-label.
How is PT-141 dosed?
As Vyleesi, it's a subcutaneous auto-injector taken on demand at least 45 minutes before activity, with a defined maximum frequency (not daily). Research-market versions also come as a nasal spray. This is educational, not dosing advice.
What are the side effects of PT-141?
Most commonly nausea (especially early), flushing and headache. It can transiently raise blood pressure (cautioned in cardiovascular disease) and cause temporary skin/gum darkening with repeated use via MC1R.
Is PT-141 FDA-approved?
Yes — as Vyleesi, for HSDD in premenopausal women. Use in men is off-label, and research-market PT-141 is unapproved material.
References & further reading
- PT-141 (bremelanotide): melanocortin-based approach (Superpower)
- PT-141 for sexual health — mechanism overview (Meto)
- PT-141 (bremelanotide) clinical guide for physicians (Enavvi)
Want Coach Cam's exact PT-141 protocol?
Dosing schedules, stacking, cycle timing and my personal notes live inside the Academy — plus the full interactive Vault of 237 compounds & 350 supplements.
Join the Academy — $10/mo →What PT-141 is used for
PT-141 appears under 1 goal in the Vault’s goal router, grouped by the mechanism it works through rather than by how much trial evidence exists. Each link opens that pathway in full, with the alternatives beside it and the bloodwork that tests it.